Free from Publisher

A pilot study of allogeneic hematopoietic stem cell transplantation for intermediated-risk acute myeloid leukemia patients

MJ Oh, DY Shin, Y Koh, J Hong, I Kim, SS Yoon… - in vivo, 2021 - iv.iiarjournals.org
Background/Aim: For intermediate risk acute myeloid leukemia patients, allogeneic
hematopoietic stem cell transplantation (alloSCT) and chemotherapy are equally …
被引用次数：2 相关文章
[PDF] iiarjournals.org

[PDF][PDF] A Pilot Study of Allogeneic Hematopoietic Stem Cell Transplantation for Intermediated-risk Acute Myeloid Leukemia Patients

MIJIN OH, DY SHIN, Y KOH, J HONG, I KIM… - in vivo, 2021 - iv.iiarjournals.org
Background/Aim: For intermediate risk acute myeloid leukemia patients, allogeneic
hematopoietic stem cell transplantation (alloSCT) and chemotherapy are equally …

A pilot study of allogeneic hematopoietic stem cell transplantation for intermediated-risk acute myeloid leukemia patients

MJ Oh, DY Shin, Y Koh, J Hong, I Kim, SS Yoon… - In …, 2021 - snucm.elsevierpure.com
Background/Aim: For intermediate risk acute myeloid leukemia patients, allogeneic
hematopoietic stem cell transplantation (alloSCT) and chemotherapy are equally …

A Pilot Study of Allogeneic Hematopoietic Stem Cell Transplantation for Intermediated-risk Acute Myeloid Leukemia Patients

MJ Oh, DY Shin, Y Koh, J Hong, I Kim… - In vivo (Athens …, 2021 - pubmed.ncbi.nlm.nih.gov
Background/aim For intermediate risk acute myeloid leukemia patients, allogeneic
hematopoietic stem cell transplantation (alloSCT) and chemotherapy are equally …
[HTML] nih.gov

[HTML][HTML] A Pilot Study of Allogeneic Hematopoietic Stem Cell Transplantation for Intermediated-risk Acute Myeloid Leukemia Patients

MIJIN OH, DY SHIN, Y KOH, J HONG, I KIM… - In Vivo, 2021 - ncbi.nlm.nih.gov
Background/Aim: Background/Aim: For intermediate risk acute myeloid leukemia patients,
allogeneic hematopoietic stem cell transplantation (alloSCT) and chemotherapy are equally …

A Pilot Study of Allogeneic Hematopoietic Stem Cell Transplantation for Intermediated-risk Acute Myeloid Leukemia Patients.

MIJIN OH, DY SHIN, Y KOH, J HONG, I KIM… - In …, 2021 - search.ebscohost.com
Abstract Background/Aim: For intermediate risk acute myeloid leukemia patients, allogeneic
hematopoietic stem cell transplantation (alloSCT) and chemotherapy are equally …

A Pilot Study of Allogeneic Hematopoietic Stem Cell Transplantation for Intermediated-risk Acute Myeloid Leukemia Patients.

MJ Oh, DY Shin, Y Koh, J Hong, I Kim… - In Vivo (Athens …, 2021 - europepmc.org
Results There were no differences between the two groups with regards to relapse-free
survival (p= 0.507) and overall survival (p= 0.798). There were more chronic graft-versus …